Intravenous zoledronate for postmenopausal osteoporosis

To determine the efficacy and safety of zoledronic acid therapy in the prevention and treatment of postmenopausal osteoporosis compared to placebo or active comparator (other bisphosphonates).

This is a protocol.

Health topics:

Rheumatology > Osteoporosis > Pharmacological therapies

Published:

20 January 2010

Authors:

Albergaria B-H, Gomes Silva BN, Atallah ÁN, Fernandes Moça Trevisani V

Primary Review Group:

Musculoskeletal Group

See the full Review on

the Cochrane Library

►

Print
PDF
Citation
Albergaria B-H, Gomes Silva BN, Atallah ÁN, Fernandes Moça Trevisani V. Intravenous zoledronate for postmenopausal osteoporosis. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD008332. DOI: 10.1002/14651858.CD008332

Don't show again

What role do you identify with the most?

General public, patient, or care giver

Health practitioner

Researcher

Policy Maker

We are collecting information on visitors to our website to ensure Cochrane resources meet the needs of our users. Your data will be anonymised for processing, will be stored securely, and will not be shared with any third parties.